Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

153.30 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Mar 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 279
Open 153.30
Bid (Size) 153.40 (1)
Ask (Size) 153.91 (2)
Prev. Close 153.30
Today's Range 153.30 - 153.30
52wk Range 150.11 - 186.69
Shares Outstanding 2,628,679,824
Dividend Yield 2.64%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
It's a Mistake to Ignore the Growth Potential of These 3 Dividend Stocks
Coca-Cola, J&J, and IBM are still solid long-term income investments. 
Via The Motley Fool
3 Blue-Chip Stocks to Buy for Stability and Safety
While there’s no such thing as 100% safe blue-chip stocks, these three are better than most when seeking to preserve capital. 
Via InvestorPlace

Performance

YTD
-13.97%
-13.97%
1 Month
-1.50%
-1.50%
3 Month
-13.60%
-13.60%
6 Month
-7.48%
-7.48%
1 Year
-13.79%
-13.79%

More News

Read More
Impact Biomedical Preparing A Potential Spinoff — What Does This Mean For Investors Of Holding Company DSS, Inc (NYSE American: DSS)?
Via Benzinga
Better Buy: AbbVie vs. Johnson & Johnson
Via The Motley Fool
Study Shows 186 Banks Are On The Brink Of Failure
Via Talk Markets
Looking At Johnson & Johnson's Recent Unusual Options Activity
Via Benzinga
Ready to Buy the Dip? Johnson & Johnson Stock Is a Smart Buy
Via The Motley Fool
Looking Into Johnson & Johnson's Recent Short Interest
Via Benzinga
Johnson & Johnson Unusual Options Activity
Via Benzinga
New Regional Director for EMEA to Drive Next Stage of Growth Across the Region for Jeron Nurse Call Systems
Via PRLog
Topics Economy
Exposures Supply Chain
Binance Suspends Trading, European Bank Trouble, Twitter To Remove Legacy Verified Checkmarks: Today's Top Stories
Via Benzinga
Johnson & Johnson Loses Key Tuberculosis Drug Patent In India, Makes Way For Domestic Generic Players
Via Benzinga
Have $1,000? 2 Smart Stocks to Buy This Month
Via The Motley Fool
3 Safe Dow Dividend Stocks to Buy Now
Via The Motley Fool
Think the Bear Market Is Over? Here's How to Invest $5,000
Via The Motley Fool
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via TheNewswire.com
Exposures Product Safety
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via News Direct
Exposures Product Safety
2 Stocks That Should Be Better Buys After Their Spinoffs This Year
Via The Motley Fool
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
Via Benzinga
3 Dow Stocks Near 52-Week Lows That Look Like Bargains Now
Via The Motley Fool
Top 8 Stocks To Profit From Rising Interest Rates
Via Talk Markets
3 Retirement Investing Moves to Help Get You Back on Track
Via The Motley Fool
5 Stocks You Can Confidently Invest $500 in Right Now
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.